IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation
IN8BIO Inc. has released a corporate presentation detailing advancements in its gamma-delta T cell therapies. Updates include clinical milestones for acute myeloid leukemia and glioblastoma programs, with significant data expected in 2026. Autoimmune indications are on hold, with potential IND-enabling studies in 2026. Further details are available in SEC filings.
IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia (AML) and glioblastoma (GBM). For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company’s recent SEC filings. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
